Literature DB >> 8842052

Determination of the composition of delavirdine mesylate polymorph and pseudopolymorph mixtures using 13C CP/MAS NMR.

P Gao1.   

Abstract

PURPOSE: The application of solid-state nuclear magnetic resonance for the quantitation of relative amounts of delavirdine mesylate (DLV-M) polymorph and/or pseudopolymorph in their binary mixtures is presented.
METHODS: 13C CP (cross-polarization)/MAS (magic angle spinning) NMR techniques were employed for quantitation.
RESULTS: 13C CP/MAS NMR spectra of three DLV-M solid forms (VIII, XI, and XII) revealed distinct differences in chemical shifts and peak splitting characteristics. Resonances of isopropyl methyl carbons of DLV-M were diagnostic of each form; resonance intensities were utilized to determine the composition of two series of DLV-M solid form mixtures (VIII and XI; XII and XI) over a dynamic concentration range (1-50%). The empirical detection limit of form VIII, or XII, in a dominant form XI environment was about 2-3% (w/w). Quantitations were obtained using appropriate analytical procedures, which took into account the differences of TCH and T1pH between the two forms. Quantitative results obtained using either the peak area or peak height were examined, and, in general, were satisfactory.
CONCLUSIONS: The methodology and analytical procedure developed in this study are generally applicable to quantitative analysis using 13C CP/MAS NMR for pharmaceutical solids, including bulk drug substances, and dosage forms. Reliable measurement of NMR relaxation times (T1pH) and CP rate constants (TCH) of individual forms is a critical component in this application.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842052     DOI: 10.1023/a:1016027212156

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  7 in total

Review 1.  Physical characterization of pharmaceutical solids.

Authors:  H G Brittain; S J Bogdanowich; D E Bugay; J DeVincentis; G Lewen; A W Newman
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

Review 2.  Pharmaceutical solids: a strategic approach to regulatory considerations.

Authors:  S Byrn; R Pfeiffer; M Ganey; C Hoiberg; G Poochikian
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

3.  Solid-state nuclear magnetic resonance (NMR) spectra of pharmaceutical dosage forms.

Authors:  P J Saindon; N S Cauchon; P A Sutton; C J Chang; G E Peck; S R Byrn
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

Review 4.  Solid-state nuclear magnetic resonance spectroscopy: theory and pharmaceutical applications.

Authors:  D E Bugay
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

5.  U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.

Authors:  T J Dueweke; S M Poppe; D L Romero; S M Swaney; A G So; K M Downey; I W Althaus; F Reusser; M Busso; L Resnick
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

6.  Quantitation of the relative amounts of anhydrous carbamazepine (C15H12N2O) and carbamazepine dihydrate (C15H12N2O.2H2O) in a mixture by solid-state nuclear magnetic resonance (NMR).

Authors:  R Suryanarayanan; T S Wiedmann
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

7.  Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E.

Authors:  I W Althaus; J J Chou; A J Gonzales; M R Deibel; K C Chou; F J Kezdy; D L Romero; R C Thomas; P A Aristoff; W G Tarpley
Journal:  Biochem Pharmacol       Date:  1994-06-01       Impact factor: 5.858

  7 in total
  5 in total

1.  Tablet dissolution affected by a moisture mediated solid-state interaction between drug and disintegrant.

Authors:  B R Rohrs; T J Thamann; P Gao; D J Stelzer; M S Bergren; R S Chao
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

2.  A 31P CP/MAS NMR study on dehydration of disodium clodronate tetrahydrate.

Authors:  J T Timonen; E Pohjala; H Nikander; T T Pakkanen
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

3.  Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.

Authors:  K Kimura; F Hirayama; H Arima; K Uekama
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

4.  Characterization of three crystalline forms (VIII, XI, and XII) and the amorphous form (V) of delavirdine mesylate using 13C CP/MAS NMR.

Authors:  P Gao
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

5.  Ultrafast 1H MAS NMR Crystallography for Natural Abundance Pharmaceutical Compounds.

Authors:  Jochem Struppe; Caitlin M Quinn; Sucharita Sarkar; Angela M Gronenborn; Tatyana Polenova
Journal:  Mol Pharm       Date:  2020-01-13       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.